ICMR hands over homegrown cervical pre-cancer treatment, vaccine technologies to pharma firms

ICMR licensed SHetA2, a non-surgical treatment for cervical pre-cancer (CIN), to Emcure Pharmaceuticals.

ICMR licensed two next-generation vaccines from NIRBI Kolkata to Biological E: one against typhoid and another targeting typhoid, paratyphoid, and Shigella.

The technologies were transferred under ICMR's Patent Mitra initiative to convert government-funded research into marketable products.

SHetA2 selectively destroys HPV-infected cells while sparing healthy cells, offering a less invasive alternative to surgery.

The vaccines aim to reduce dependence on imported technologies and improve access to affordable treatments in India.